Treatment of therapy-related acute myeloid leukemia occurring in elderly non-Hodgkin lymphoma patients with low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor

Leukemia Research

Volumn 33, Issue 1, 2009, Pages 197-200

  Tatetsu, Hiro ^a   Matsuno, Fumihiko ^a   Takatsu, Noritaka ^a   Miyake, Hirosada ^a   Hoshino, Koyu ^a   Nosaka, Kisato ^a   Horikawa, Kentaro ^a   Hata, Hiroyuki ^a   Mitsuya, Hiroaki ^a   Asou, Norio ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACLARUBICIN; ANTINEOPLASTIC AGENT; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ANAMNESIS; B CELL LYMPHOMA; CANCER PATIENT; CANCER STAGING; CASE REPORT; COMBINATION CHEMOTHERAPY; DIFFUSE LARGE B CELL LYMPHOMA; FEMALE; HUMAN; LETTER; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ACLARUBICIN; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; NEOPLASMS, SECOND PRIMARY;

EID: 55049108635     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.04.002     Document Type: Letter

References (8)

1. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 235-242
2. Saito K., Nakamura Y., Aoyagi M., et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol 71 (2000) 238-244
3. Qian S.X., Li J.Y., Tian T., et al. Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia. Leuk Res 31 (2007) 1383-1388
4. Armitage J.O., Carbone P.P., Connors J.M., et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 21 (2003) 897-906
5. Haferlach T., Schoch C., Loffler H., et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol 21 (2003) 256-265
6. Smith S.M., Le Beau M.M., Huo D., et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 102 (2003) 43-52
7. Schoch C., Kern W., Schnittger S., et al. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 18 (2004) 120-125
8. Hori S., Shirai M., Hirano S., et al. Antitumor activity of new anthracycline antibiotics, aclacinomycin-A and its analogs, and their toxicity. Gann 68 (1977) 685-690